Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 6/20 | 0.41 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.36 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.36 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.36 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.35 |
| ▸ | PTPN6 | P29350 | 2/20 | 0.35 |
| ▸ | DUSP3 | P51452 | 2/20 | 0.35 |
| ▸ | PTPN22 | Q9Y2R2 | 2/20 | 0.35 |
| ▸ | PTPRC | P08575 | 1/20 | 0.35 |
| ▸ | PTPN9 | P43378 | 1/20 | 0.35 |
| ▸ | TACR3 | P29371 | 8/20 | 0.35 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4334488 | 0.92 | PTGER1 (0.37) | PTPN11PTGER1CSNK1DCSNK1ETACR3 | |
| SCHEMBL4340976 | 0.88 | MAPT (0.38) | PTGER1CSNK1DCSNK1ETACR3KDM4E | |
| SCHEMBL4332632 | 0.83 | PTPN11 (0.41) | PTPN11PTGER1CSNK1DCSNK1EPTPN2 | |
| SCHEMBL4334945 | 0.82 | CSNK1E (0.38) | PTGER1CSNK1DCSNK1ETACR3 | |
| SCHEMBL4343214 | 0.79 | CSNK1E (0.35) | PTGER1CSNK1DCSNK1ETACR3KDM4E | |
| SCHEMBL4343207 | 0.74 | PTGER1 (0.38) | PTGER1CSNK1DCSNK1ETACR3KDM4E | |
| SCHEMBL4336324 | 0.74 | PTGER1 (0.38) | PTGER1CSNK1DCSNK1ETACR3KDM4E | |
| SCHEMBL4336462 | 0.72 | CSNK1D (0.38) | PTGER1CSNK1DTACR3KDM4E | |
| SCHEMBL4348125 | 0.70 | PTGER1 (0.41) | PTGER1CSNK1DCSNK1EKDM4E | |
| SCHEMBL4328987 | 0.69 | CTSA (0.41) | PTGER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7541376-B2 | 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-02 | — | — | US | disclosed |
| US-20050282880-A1 | Novel 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282880-A1 | Novel 1H-indazole compounds | MAPK1, MAPK3, MAPK13 | PTPN11 2017/4885PTGER1 3143/4885CSNK1D 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.